The second-generation mTOR kinase inhibitor INK128 exhibits anti-inflammatory activity in lipopolysaccharide-activated RAW 264.7 cells.

Inflammation

Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632, China.

Published: June 2014

Cross-talk between the mTOR (mechanistic target of rapamycin) and NF-κB (nuclear factor kappa-B) pathways has been reported to regulate macrophage responses to lipopolysaccharide (LPS). In this study, we aimed to explore the effect of INK128, a second-generation inhibitor of mTOR, on the inflammatory cytokine production in LPS-stimulated RAW 264.7 cells. Our data showed that INK128 strikingly inhibited the phosphorylation of p70S6K, 4E-BP1 and AKTSer473 in both unstimulated and LPS-stimulated cells. Although it increased the phosphorylation levels of inhibitor kappa-B (IκB) in LPS-stimulated cells, INK128 did not significantly change the levels of NF-κB phosphorylation. In addition, LPS-induced expression of IL-1β and IL-6 was markedly suppressed by INK128 at both mRNA and protein levels. However, the expression of Tumor necrosis factor-alpha (TNF-α protein), but not its mRNA level, was suppressed by this reagent. Our results suggest that the mTOR inhibitor INK128 not only regulates the NF-κB signaling but also influences the inflammatory cytokine expression at both transcriptional and translational levels.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10753-013-9794-9DOI Listing

Publication Analysis

Top Keywords

inhibitor ink128
8
raw 2647
8
2647 cells
8
inflammatory cytokine
8
lps-stimulated cells
8
ink128
6
second-generation mtor
4
mtor kinase
4
inhibitor
4
kinase inhibitor
4

Similar Publications

β-sitosterol alleviates atherosclerosis by regulating catalase.

Heliyon

August 2024

Department of Outpatient, The First People's Hospital of Yunnan, No.157, Jinbi road, Kunming, 650000, Yunnan, China.

The aim of this study is to investigate the main active components of Gegen () on atherosclerosis and its mechanism of action. Bioinformatics analysis showed that β-sitosterol was the most likely active ingredient to mediate the anti-atherosclerotic effects. experiments showed that β-sitosterol inhibited plaque formation and platelet activation, and decreased serum total cholesterol (TC) and triglyceride (TG) levels.

View Article and Find Full Text PDF

Background: There are limited therapeutic options for patients with recurrent/metastatic anaplastic thyroid carcinoma (ATC), and radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) refractory to multi-kinase inhibitors. This multi-center trial evaluated sapanisertib, a next generation oral kinase inhibitor of mTOR complexes 1/2, in ATC and RAIR DTC.

Methods: A safety run-in phase I was followed by non-randomized phase II trial in ATC, with an exploratory cohort in RAIR DTC.

View Article and Find Full Text PDF

Background: The PI3K/AKT/mTOR pathway is frequently altered at genomic level in metastatic urothelial carcinoma (mUC). Since mTOR is the last protein in the PI3K signaling cascade, it may have the largest impact on the pathway and has been a focus of targeted therapies. Sapanisertib (FTH-003/TAK-228) is an oral highly selective mTOR1 and mTOR2 inhibitor.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated the safety and effectiveness of combining alisertib and sapanisertib in patients with difficult-to-treat solid tumors, focusing on pancreatic adenocarcinoma.
  • - A total of 31 patients were treated, and while similar side effects to previous studies were noted, only one patient with breast cancer showed a significant improvement, and pancreatic cancer patients had modest treatment responses.
  • - The findings suggest that targeting proteins involved in cell cycle regulation (Aurora A kinase) and tumor growth (mTOR) had limited overall clinical impact, but responses varied based on tumor characteristics and patient treatment history.
View Article and Find Full Text PDF

Objectives: Some drugs that augment cell-intrinsic defenses or modulate cell death/survival pathways have been reported to selectively kill cells infected with HIV or Simian Immunodeficiency Virus (SIV), but comparative studies are lacking. We hypothesized that these drugs may differ in their ability to kill cells infected with intact and defective proviruses.

Design: To investigate this hypothesis, drugs were tested ex vivo on peripheral blood mononuclear cells (PBMC) from nine antiretroviral therapy (ART)-suppressed individuals.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!